Understanding the incremental value of novel diagnostic tests for tuberculosis

Nature

Volumn 528, Issue 7580, 2015, Pages S60-S67

  Arinaminpathy, Nimalan ^a   Dowdy, David ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE TRANSMISSION; HEALTH CARE; INFECTIOUS DISEASE; MORTALITY; SYMPTOM; TUBERCULOSIS;

ARTICLE; BACTERIAL TRANSMISSION; CONCEPTUAL FRAMEWORK; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; HEALTH CARE SYSTEM; HUMAN; INCREMENTAL DIAGNOSTIC VALUE; MEDICAL HISTORY; PATIENT ATTITUDE; PRIORITY JOURNAL; TUBERCULOSIS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE PLANNING; SENSITIVITY AND SPECIFICITY; STANDARDS; TIME; TRANSMISSION;

COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; HEALTH RESOURCES; HUMANS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUBERCULOSIS;

EID: 84949217336     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16045     Document Type: Article

References (82)

1. World Health Organization. Global Tuberculosis Report, 2014 (WHO, 2014).
2. Herbert, N. et al. World TB Day 2014: finding the missing 3 million. Lancet 383, 1016-1018 (2014).
3. Lawn, S. D. et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect. Dis. 13, 349-361 (2013).
4. TB CARE I. International Standards for Tuberculosis Care 3rd Edn (TB CARE I, 2014).
5. Steingart, K. R. et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect. Dis. 6, 570-581 (2006).
6. Cobelens, F. et al. Which new diagnostics for tuberculosis, and when? J. Infect. Dis. 205, S191-S198 (2012).
7. Pho, M. T. et al. Optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of Uganda. PLoS ONE 10, e0122574 (2015).
8. Churchyard, G. et al. Effect of Xpert MTB/RIF on early mortality in adults with suspect-ed TB: a pragmatic randomized trial. Proc. Conference on Retroviruses and Opportun-istic Infections (IAS-USA, 2014).
9. Theron, G. et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/ RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, ran-domised, controlled trial. Lancet 383, 424-435 (2014).
10. Durovni, B. et al. Impact of replacing smear microscopy with Xpert MTB/RIF for diag-nosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial. PLoS Med. 11, e1001766 (2014).
11. Sachdeva, K. S. et al. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India. PLoS ONE 10, e0126065 (2015).
12. Steingart, K. R. et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and ri-fampicin resistance in adults. Cochrane Database Syst. Rev. 1, CD009593 (2013).
13. Theron, G. et al. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect. Dis. 14, 527-532 (2014).
14. Sun, A. Y., Denkinger, C. M. and Dowdy, D. W. The impact of novel tests for tuberculosis depends on the diagnostic cascade. Eur. Respir. J. 44, 1366-1369 (2014).
15. Menzies, N. A., Cohen, T., Murray, M. and Salomon, J. A. Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis. Lancet Infect. Dis. 15, 16-17 (2015).
16. Dye, C. The potential impact of new diagnostic tests on tuberculosis epidemics. In-dian J. Med. Res. 135, 737-744 (2012).
17. Langley, I. et al. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrat-ed modelling approach. Lancet Glob. Health. 2, e581-e591 (2014).
18. Dowdy, D. W. and Chaisson, R. E. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull. World Health Organ. 87, 296-304 (2009).
19. Dowdy, D. W., Basu, S. and Andrews, J. R. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am. J. Respir. Crit. Care Med. 187, 543-551 (2013).
20. Zwerling, A. et al. Modeling of novel diagnostic strategies for active tuberculosis -a systematic review: current practices and recommendations. PLoS ONE 9, e110558 (2014).
21. Garnett, G. P., Cousens, S., Hallett, T. B., Steketee, R. and Walker, N. Mathematical mod-els in the evaluation of health programmes. Lancet 378, 515-525 (2011).
22. Dowdy, D. W., Dye, C. and Cohen, T. Data needs for evidence-based decisions: a tuber-culosis modelers wish list. Int. J. Tuberc. Lung Dis. 17, 866-877 (2013).
23. Dye, C., Garnett, G. P., Sleeman, K. and Williams, B. G. Prospects for worldwide tu-berculosis control under the WHO DOTS strategy. Lancet 352, 1886-1891 (1998).
24. Dowdy, D. W., Chaisson, R. E., Moulton, L. H. and Dorman, S. E. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 20, 751-762 (2006).
25. Abu-Raddad, L. J. et al. Epidemiological benefits of more-effective tuberculosis vac-cines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA. 106, 13980-13985 (2009).
26. Boehme, C. C. et al. Feasibility, diagnostic accuracy, and effectiveness of decentral-ised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug re-sistance: a multicentre implementation study. Lancet 377, 1495-1505 (2011).
27. Boehme, C. C. et al. Rapid molecular detection of tuberculosis and rifampin resist-ance. N. Engl. J. Med. 363, 1005-1015 (2010).
28. Storla, D. G., Yimer, S. and Bjune, G. A. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 8, 15 (2008).
29. Sreeramareddy, C. T., Panduru, K. V., Menten, J. and Van den Ende, J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect. Dis. 9, 91 (2009).
30. Salje, H. et al. The importance of implementation strategy in scaling up Xpert MTB/ RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model. PLoS Med. 11, e1001674 (2014).
31. Sachdeva, K. S. et al. The potential impact of up-front drug sensitivity testing on In-dias epidemic of multi-drug resistant tuberculosis. PLoS ONE 10, e0131438 (2015).
32. Lin, H. H., Dowdy, D., Dye, C., Murray, M. and Cohen, T. The impact of new tuberculo-sis diagnostics on transmission: why context matters. Bull. World Health Organ. 90, 739-747A (2012).
33. Mandal, S. and Arinaminpathy, N. Transmission modeling and health systems: the case of TB in India. Int. Health 7, 114-120 (2015).
34. McNerney, R., Cunningham, J., Hepple, P. and Zumla, A. New tuberculosis diagnostics and rollout. Int. J. Infect. Dis. 32, 81-86 (2015).
35. Grobbee, D. E. and Hoes, A. W. Clinical Epidemiology: Principles, Methods, and Applica-tions for Clinical Research (Jones and Bartlett, 2009).
36. Phelps, C. E. and Mushlin, A. I. Focusing technology assessment using medical decision theory. Med. Decis. Making 8, 279-289 (1988).
37. Laking, G., Lord, J. and Fischer, A. The economics of diagnosis. Health Econ. 15, 1109-1120 (2006).
38. Van den Bruel, A., Cleemput, I., Aertgeerts, B., Ramaekers, D. and Buntinx, F. The evalu-ation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J. Clin. Epidemiol. 60, 1116-1122 (2007).
39. vant Hoog, A. H. et al. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis. PLoS ONE 8, e82786 (2013).
40. Millman, A. J. et al. Rapid molecular testing for TB to guide respiratory isolation in the U.S.: a cost-benefit analysis. PLoS ONE 8, e79669 (2013).
41. Cobelens, F., van Kampen, S., Ochodo, E., Atun, R. and Lienhardt, C. Research on im-plementation of interventions in tuberculosis control in low-and middle-income countries: a systematic review. PLoS Med. 9, e1001358 (2012).
42. Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M. and Lonnroth, K. Financial burden for tuberculosis patients in low-and middle-income countries: a systematic review. Eur. Respir. J. 43, 1763-1775 (2014).
43. Bauer, M., Leavens, A. and Schwartzman, K. A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Qual. Life Res. 22, 2213-2235 (2013).
44. Getahun, H., Matteelli, A., Chaisson, R. E. and Raviglione, M. Latent Mycobacterium tuberculosis infection. N. Engl. J. Med. 372, 2127-2135 (2015).
45. Corbett, E. L. et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med. 4, e22 (2007).
46. Mao, T. E. et al. Cross-sectional studies of tuberculosis prevalence in Cambodia between 2002 and 2011. Bull. World Health Organ. 92, 573-581 (2014).
47. Ho, J., Marks, G. B. and Fox, G. J. The impact of sputum quality on tuberculosis diagnosis: a systematic review. Int. J. Tuberc. Lung Dis. 19, 537-544 (2015).
48. Gardy, J. L. et al. Whole-genome sequencing and social-network analysis of a tuberculo-sis outbreak. N. Engl. J. Med. 364, 730-739 (2011).
49. Ayles, H. et al. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS ONE 4, e5602 (2009).
50. Hoa, N. B. et al. Yield of interview screening and chest X-ray abnormalities in a tubercu-losis prevalence survey. Int. J. Tuberc. Lung Dis. 16, 762-767 (2012).
51. Banda, H. T. et al. Prevalence of tuberculosis in TB suspects with short duration of cough. Trans. R. Soc. Trop. Med. Hyg. 92, 161-163 (1998).
52. Lonnroth, K. et al. Towards tuberculosis elimination: an action framework for low-inci-dence countries. Eur. Respir. J. 45, 928-952 (2015).
53. Denkinger, C. M. et al. Defining the needs for next generation assays for tuberculosis. J. Infect. Dis. 211 (Suppl 2), S29-S38 (2015).
54. Morrison, J., Pai, M. and Hopewell, P. C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-in-come countries: a systematic review and meta-analysis. Lancet Infect. Dis. 8, 359-368 (2008).
55. Lawn, S. D., Kerkhoff, A. D. and Wood, R. Progression of subclinical culture-positive tuber-culosis to symptomatic disease in HIV-infected individuals. AIDS 25, 2190-2191 (2011).
56. Harries, A. D. et al. Management of pulmonary tuberculosis suspects with negative sputum smears and normal or minimally abnormal chest radiographs in resource-poor settings. Int. J. Tuberc. Lung Dis. 2, 999-1004 (1998).
57. Wallis, R. S. et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375, 1920-1937 (2010).
58. Garcia-Basteiro, A. L. and Cobelens, F. Triage tests: a new priority for tuberculosis diagnos-tics. Lancet Respir. Med. 3, 177-178 (2015).
59. Kik, S. V., Denkinger, C. M., Jefferson, C., Ginnard, J. and Pai, M. Potential market for nov-el tuberculosis diagnostics: worth the investment? J. Infect. Dis. 211 (Suppl 2), S58-S66 (2015).
60. Pai, N. P. and Pai, M. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discov. Med. 13, 35-45 (2012).
61. Adang, E., Voordijk, L., Jan van der Wilt, G. and Ament, A. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Health Policy 74, 146-156 (2005).
62. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J. and Stoddart, G. L. In Methods for the Economic Evaluation of Health Care Programmes 396 (Oxford Univ. Press, 2005).
63. Azman, A. S., Golub, J. E. and Dowdy, D. W. How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. BMC Med. 12, 216 (2014).
64. Behr, M. A. et al. Transmission of Mycobacterium tuberculosis from patients smear-nega-tive for acid-fast bacilli. Lancet 353, 444-449 (1999).
65. Dowdy, D. W., Golub, J. E., Chaisson, R. E. and Saraceni, V. Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. Proc. Natl Acad. Sci. USA. 109, 9557-9562 (2012).
66. Glaziou, P. et al. Tuberculosis prevalence surveys: rationale and cost. Int. J. Tuberc. Lung Dis. 12, 1003-1008 (2008).
67. Schnippel, K. et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory-vs. clinic-based roll-out in South Africa. Trop. Med. Int. Health 17, 1142-1151 (2012).
68. Travis, P. et al. Overcoming health-systems constraints to achieve the Millennium Devel-opment Goals. Lancet 364, 900-906 (2004).
69. Sohn, H. et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin. Infect. Dis. 58, 970-976 (2014).
70. Cowan, J. et al. Implementing rapid testing for tuberculosis in Mozambique. Bull. World Health Organ. 93, 125-130 (2015).
71. Page-Shipp, L. et al. Successes, challenges and lessons from a novel deployment of Xpert((R)) MTB/RIF at a major South African public event. Int. J. Tuberc. Lung Dis. 18, 438-440 (2014).
72. Kelly, J. D. et al. Xpert MTB/RIF false detection of rifampin-resistant tuberculosis from prior infection. Am. J. Respir. Crit. Care Med. 190, 1316-1318 (2014).
73. Nakiyingi, L. et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS ONE 8, e74023 (2013).
74. Yoon, C. et al. Impact of Xpert MTB/RIF testing on tuberculosis management and out-comes in hospitalized patients in Uganda. PLoS ONE 7, e48599 (2012).
75. Dowdy, D. W., Azman, A. S., Kendall, E. A. and Mathema, B. Transforming the fight against tuberculosis: targeting catalysts of transmission. Clin. Infect. Dis. 59, 1123-1129 (2014).
76. Jenkins, H. E. et al. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur. Respir. J. 42, 1291-1301 (2013).
77. van Soolingen, D. Whole-genome sequencing of Mycobacterium tuberculosis as an epi-demiological marker. Lancet Respir. Med. 2, 251-252 (2014).
78. Walker, T. M., Monk, P., Smith, E. G. and Peto, T. E. Contact investigations for outbreaks of Mycobacterium tuberculosis: advances through whole genome sequencing. Clin. Micro-biol. Infect. 19, 796-802 (2013).
79. Merker, M. et al. Evolutionary history and global spread of the Mycobacterium tuberculo-sis Beijing lineage. Nature Genet. 47, 242-249 (2015).
80. Grandjean, L. et al. Transmission of multidrug-resistant and drug-susceptible tubercu-losis within households: a prospective cohort study. PLoS Med. 12, e1001843 (2015).
81. Zelner, J. L. et al. Age-specific risks of tuberculosis infection from household and com-munity exposures and opportunities for interventions in a high-burden setting. Am. J. Epidemiol. 180, 853-861 (2014).
82. Ravishankar, N. et al. Financing of global health: tracking development assistance for health from 1990 to 2007. Lancet 373, 2113-2124 (2009).